Epitalon Identified in Illicit Preparations, Raising Public Safety Concerns

Epitalon, a synthetic tetrapeptide (a small protein fragment made of four amino acids), has been widely discussed for its purported benefits in anti-aging, cancer treatment, and managing Retinitis Pigmentosa (a genetic eye disease causing progressive vision loss). Despite these claims, its presence in unregulated products poses significant risks to public health. This study aimed to analytically confirm the presence of Epitalon in illegally marketed pharmaceutical preparations to assess the scope of this issue.

The comprehensive LC-MS analysis successfully identified Epitalon (also known as Ala-Glu-Asp-Gly or AEDG) in both of the investigated illegal preparations. The molecular weight and fragmentation patterns observed were unequivocally consistent with the known structure of Epitalon, providing definitive evidence of its presence. This confirmed the unauthorized inclusion of Epitalon in products marketed without proper regulatory oversight, highlighting potential public health risks associated with unverified substances. The findings indicate that these illicit products contained the active peptide, suggesting a deliberate attempt by manufacturers to mimic legitimate pharmaceutical formulations without adhering to crucial safety and quality standards, posing a significant risk to consumers. This lack of regulation means consumers are exposed to unknown concentrations and potential impurities.